396 related articles for article (PubMed ID: 37934320)
21. Psychedelic drugs for psychiatric disorders.
da Costa SC; Oesterle T; Rummans TA; Richelson E; Gold M
J Neurol Sci; 2022 Sep; 440():120332. PubMed ID: 35841696
[TBL] [Abstract][Full Text] [Related]
22. Ketamine for Depression: Advances in Clinical Treatment, Rapid Antidepressant Mechanisms of Action, and a Contrast with Serotonergic Psychedelics.
Kojic M; Saelens J; Kadriu B; Zarate CA; Kraus C
Curr Top Behav Neurosci; 2022; 56():141-167. PubMed ID: 35312993
[TBL] [Abstract][Full Text] [Related]
23. Antidepressant, Antipsychotic, and Hallucinogen Drugs for the Treatment of Psychiatric Disorders: A Convergence at the Serotonin-2A Receptor.
Howland RH
J Psychosoc Nurs Ment Health Serv; 2016 Jul; 54(7):21-4. PubMed ID: 27362381
[TBL] [Abstract][Full Text] [Related]
24. [Classic psychedelic drugs and their potential therapeutic effect].
Bayat M
Ugeskr Laeger; 2017 Sep; 179(37):. PubMed ID: 28918777
[TBL] [Abstract][Full Text] [Related]
25. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.
Dos Santos RG; Bouso JC; Alcázar-Córcoles MÁ; Hallak JEC
Expert Rev Clin Pharmacol; 2018 Sep; 11(9):889-902. PubMed ID: 30102078
[TBL] [Abstract][Full Text] [Related]
26. Next generation antidepressants with novel mechanisms for treatment resistant depression.
Chen MH; Tu PC; Su TP
Prog Brain Res; 2023; 278():149-168. PubMed ID: 37414491
[TBL] [Abstract][Full Text] [Related]
27. Antidepressant Effects of Psilocybin in the Absence of Psychedelic Effects.
Rosenblat JD; Leon-Carlyle M; Ali S; Husain MI; McIntyre RS
Am J Psychiatry; 2023 May; 180(5):395-396. PubMed ID: 36945824
[No Abstract] [Full Text] [Related]
28. Sub-acute effects of psilocybin on EEG correlates of neural plasticity in major depression: Relationship to symptoms.
Skosnik PD; Sloshower J; Safi-Aghdam H; Pathania S; Syed S; Pittman B; D'Souza DC
J Psychopharmacol; 2023 Jul; 37(7):687-697. PubMed ID: 37392016
[TBL] [Abstract][Full Text] [Related]
29. The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future.
Carhart-Harris RL; Goodwin GM
Neuropsychopharmacology; 2017 Oct; 42(11):2105-2113. PubMed ID: 28443617
[TBL] [Abstract][Full Text] [Related]
30. How to account for hallucinations in the interpretation of the antidepressant effects of psychedelics: a translational framework.
van den Berg M; Magaraggia I; Schreiber R; Hillhouse TM; Porter JH
Psychopharmacology (Berl); 2022 Jun; 239(6):1853-1879. PubMed ID: 35348806
[TBL] [Abstract][Full Text] [Related]
31. The Therapeutic Potential of Psilocybin.
Lowe H; Toyang N; Steele B; Valentine H; Grant J; Ali A; Ngwa W; Gordon L
Molecules; 2021 May; 26(10):. PubMed ID: 34063505
[TBL] [Abstract][Full Text] [Related]
32. Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial.
Sloshower J; Skosnik PD; Safi-Aghdam H; Pathania S; Syed S; Pittman B; D'Souza DC
J Psychopharmacol; 2023 Jul; 37(7):698-706. PubMed ID: 36938991
[TBL] [Abstract][Full Text] [Related]
33. Sustained effects of single doses of classical psychedelics in humans.
Knudsen GM
Neuropsychopharmacology; 2023 Jan; 48(1):145-150. PubMed ID: 35729252
[TBL] [Abstract][Full Text] [Related]
34. Serotonin 2A Receptor (5-HT
Duan W; Cao D; Wang S; Cheng J
Chem Rev; 2024 Jan; 124(1):124-163. PubMed ID: 38033123
[TBL] [Abstract][Full Text] [Related]
35. Registered clinical studies investigating psychedelic drugs for psychiatric disorders.
Siegel AN; Meshkat S; Benitah K; Lipsitz O; Gill H; Lui LMW; Teopiz KM; McIntyre RS; Rosenblat JD
J Psychiatr Res; 2021 Jul; 139():71-81. PubMed ID: 34048997
[TBL] [Abstract][Full Text] [Related]
36. Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice.
Hesselgrave N; Troppoli TA; Wulff AB; Cole AB; Thompson SM
Proc Natl Acad Sci U S A; 2021 Apr; 118(17):. PubMed ID: 33850049
[TBL] [Abstract][Full Text] [Related]
37. Human behavioral pharmacology of psychedelics.
Strickland JC; Johnson MW
Adv Pharmacol; 2022; 93():105-132. PubMed ID: 35341564
[TBL] [Abstract][Full Text] [Related]
38. [Are psychedelics fast acting antidepressant agents?].
Gründer G; Brand M; Kärtner L; Scharf D; Schmitz C; Spangemacher M; Mertens LJ
Nervenarzt; 2022 Mar; 93(3):254-262. PubMed ID: 35103814
[TBL] [Abstract][Full Text] [Related]
39. Probing the antidepressant potential of psilocybin: integrating insight from human research and animal models towards an understanding of neural circuit mechanisms.
Meccia J; Lopez J; Bagot RC
Psychopharmacology (Berl); 2023 Jan; 240(1):27-40. PubMed ID: 36564671
[TBL] [Abstract][Full Text] [Related]
40. Psychedelics and Psychedelic-Assisted Psychotherapy.
Reiff CM; Richman EE; Nemeroff CB; Carpenter LL; Widge AS; Rodriguez CI; Kalin NH; McDonald WM;
Am J Psychiatry; 2020 May; 177(5):391-410. PubMed ID: 32098487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
